• Manufacturing

Agility Life Sciences CEO makes Medicine Maker Power List debut

Prof. Claire Thompson, multi award-winning CEO of Agility Life Sciences, has been recognised as one of the Top 10 Leaders in the field of small molecules on the 2022 Medicine Maker Power List.

RoslinCT continues its growth plans by expanding its operations at Edinburgh Technopole

RoslinCT - a cell and gene therapy/ATMP CDMO, developing life-changing cell and gene therapies in Edinburgh’s BioQuarter– signs lease for 1,453 sqm additional space at Charles Darwin House at the Edinburgh Technopole.

RoslinCT Announces the Appointment of Peter Coleman as CEO

RoslinCT - a cell and gene therapy/ATMP CDMO, developing life-changing cell and gene therapies in Edinburgh’s BioQuarter – announces the appointment of Peter Coleman as CEO.

Stablepharma achieved a scientific breakthrough with a fridge-free Tetanus diphtheria (Td) vaccine

Stablepharma has achieved an important milestone with the Td-StablevaX-M™, having successfully demonstrated stability of the reformulated Td vaccine for up to 10 months at +45ºC in collaboration with our strategic partner BB–NCIPD Ltd (Bul Bio).

CN Bio introduces PhysioMimix NASH ‘in-a-box’ reagent kit

First product within new ‘in-a-box’ range, which harnesses next-generation, human-relevant Liver-on-a-Chip technology to improve the accuracy and efficiency of NASH drug discovery

Symbiosis announces successful completion of UKRI project, which will enhance the manufacturing supply chain for ATMPs within the UK

Symbiosis, a fast-growing contract manufacturing organisation (CMO) specialising in sterile global manufacture of pharmaceuticals, vaccines and biopharmaceuticals including Advanced Therapeutical Medicinal Products (ATMPs), has announced the completion of a £1.3 million collaborative UKRI-funded project as part of the medicines manufacturing challenge.

CEO Update | 28 March 2022

Last week the Chancellor delivered his Spring Statement, where there were key wins for the sector following BIA campaigning. The Chancellor announced that R&D taking place abroad for ‘regulatory and legal reasons’ would still be eligible for R&D tax relief, and it was heartening to hear him mention clinical trials as an example. The Biomedical Catalyst (BMC) 2022 Round 1 has gone live today with its first round for 2022.

Jazz Pharmaceuticals Announces Significant New Investment in UK Manufacturing

Construction begins on a new state-of-the-art manufacturing facility at Kent Science Park designed to support the manufacture of regulatory approved cannabis-based medicines. This represents a significant commitment to the UK by GW Pharmaceuticals, now part of Jazz Pharmaceuticals, investing $100 million (£75m) and creating more than 100 highly skilled jobs

LeaP & PULSE | How the BIA supported Extracellular’s start-up journey

Will Milligan recently founded Extracellular, the first dedicated manufacturing partner to support cellular agriculture. Will shares how the BIA has supported his professional development and Extracellular’s start-up journey.

Cellexus partner with Verder to upgrade bioreactor systems

Dundee-based life sciences firm, Cellexus, have partnered with Castleford-based Verder Liquids to provide pumps to be used for the acid / base pump included as standard with their CellMaker Plus and Low Flow bioreactor systems.